Sector News

Roche to beat Novartis, Pfizer to pharma throne by 2022

September 16, 2016
Life sciences

Crosstown rivals Novartis and Roche will be neck and neck for the No. 1 spot in pharma sales till 2022, with Roche ahead by a nose at the finish line, according to a new market analysis. Along the way, a 6.3% annual growth rate industrywide will take global prescription drug sales past the $1 trillion mark.

Roche is forecast to tally $52.6 billion in 2022 prescription drug sales, representing a 4% annual expansion over 2015’s total of $38.7 billion, according to EvaluatePharma’s new World Preview report. Novartis, with 2015 prescription sales of $42.5 billion, will end up with $52.5 billion at the end of the period, missing Roche’s tally by about $100 million. Pfizer, Sanofi, Johnson & Johnson, Merck and GlaxoSmithKline each follow in order, with other big-name players behind them.

But as with all forecasts, this one isn’t written in stone. Facing a more serious biosimilar threat than Novartis, Roche could find itself knocked out of the pole position, EP said. Many of the bestselling drugs in the industry, including Roche’s Rituxan and Avastin, are forecast to suffer from biosim competition by 2020.

Overall, the world’s prescription drug industry is expected to ride 6.3% growth through 2022 to $1.12 trillion, up from $741 billion in 2015. That’s as new launches “hopefully take the torch from industry’s superstars, like Harvoni, whose light is now fading,” the report said.

Roche’s immuno-oncology therapy Tecentriq is expected to be one of those, by 2022 becoming one of the world’s best-selling drugs, EP said. Gilead, Biogen and GlaxoSmithKline are the companies that have performed best on recent launches, the analysts said.

Notably, Celgene and Shire are expected to post double-digit growth over the period, according to the analysts, expanding sales by an annual clip of 16% and 19%, respectively.

Pfizer led 2015 pharma sales at $43.1 billion, a tally that’s now expected to grow to $49.1 billion by 2022, according to EP. Novartis was expected to be the top player by 2020, as of last year’s report.

EvaluatePharma sees Roche’s pipeline as the most valuable in the industry, although the Basel-based pharma’s strategy comes with risk. The company’s candidates in multiple sclerosis, Alzheimer’s, haemophilia and macular degeneration help its overall pipeline reach a value of $43.2 billion, far eclipsing Novartis’ pipeline value of $24.1 billion and AstraZeneca’s at $23.2 billion.

Companies behind those in pipeline value are Eli Lilly, AbbVie, Pfizer, Sanofi, Celgene, Biogen and J&J, respectively.

In the big picture, following a “spectacular four-year bull run,” the industry’s outlooks are more mixed moving forward, EP said, as pricing pressures take a toll in the U.S. and other “brakes” to growth loom. Among those are biosimilar threats and clinical setbacks. Spending pressures could also hamper sales growth, as healthcare systems struggle with their growing drug bills.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach